Autolus Therapeutics (AUTL) Projected to Post Earnings on Wednesday

Autolus Therapeutics (NASDAQ:AUTL) is projected to announce its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $21.0760 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:30 AM ET.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $12.92 million. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Price Performance

Shares of AUTL stock opened at $1.33 on Monday. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $4.12. The stock’s 50-day moving average is $1.51 and its two-hundred day moving average is $1.81. The firm has a market cap of $353.97 million, a P/E ratio of -1.58 and a beta of 1.84.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AUTL. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Wells Fargo & Company cut their target price on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, November 3rd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Autolus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.12.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Marex Group plc bought a new position in Autolus Therapeutics during the second quarter worth about $28,000. Bank of America Corp DE lifted its position in shares of Autolus Therapeutics by 2,891.7% during the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after buying an additional 942,540 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares in the last quarter. Geode Capital Management LLC grew its position in Autolus Therapeutics by 90.5% in the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after acquiring an additional 78,058 shares during the period. Finally, Jane Street Group LLC raised its stake in Autolus Therapeutics by 809.4% during the first quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock worth $159,000 after acquiring an additional 91,222 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.